Table 1 Summary of available best evidence on serious upper gastrointestinal complications
Treatment | Best evidence | Patient years of exposure | Number of events | PUB(% per year) |
|---|---|---|---|---|
Placebo | Meta-analysis of rofecoxib trials [31] | 112 | 3 | 2.68 |
Placebo | Meta-analysis of celecoxib trials [28] | 441 | 1 | 0.23 |
Celecoxib | Meta-analysis of celecoxib trials [28] | 7943 | 74 | 0.93 |
Etoricoxib | Meta-analysis of etoricoxib trials [29] | 4007 | 19 | 0.47 |
Lumiracoxib | RCT [15] | 6368 | 29 | 0.46 |
Rofecoxib | Meta-analysis of rofecoxib trials [31,13] | 8524 | 28 | 0.33 |
Valdecoxib | Meta-analysis of valdecoxib trials [30] | 1183 | 8 | 0.68 |
NSAID | Meta-analysis of celecoxib trials [28] | 5258 | 110 | 2.09 |
NSAID | Meta-analysis of etoricoxib trials [29] | 2230 | 23 | 1.03 |
NSAID | RCT with lumiracoxib [15] | 6845 | 83 | 1.21 |
NSAID | Meta-analysis of rofecoxib trials [31,13] | 5532 | 50 | 0.90 |
NSAID | Meta-analysis of valdecoxib trials [30] | 563 | 11 | 1.95 |